תבנית:תרופה/דוסטקסל אקטביס - Docetaxel actavis
מתוך ויקיתרופות
נתוני תרופה
במרשם 
| קבוצה פרמקולוגית (ATC4) | |
|---|---|
| מרכיב פעיל (ATC5) |
|
| צורת מתן | I.V |
| צורת מינון | CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION |
| התוויה | Breast cancer :Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylatingagent.Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastaticdisease.Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk nodenegative,breast cancer. Docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative,breast cancer.Non-small cell lung cancer:Docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinomaOvarian Cancer:Docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancer:Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancer :Docetaxel is also indicated for the treatment of esophageal cancerGastric cancer :Docetaxel is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) :• Docetaxel as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
|
| תבנית:נתוני סל/תרופה/דוסטקסל אקטביס - Docetaxel actavis | |
| ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
|---|---|
| חיפוש מאמרים | - |
|---|---|
| מידע ברשת | - |
| שם יצרן | ACTAVIS GROUP PTC EHF, ICELAND |
| שם בעל הרישום | DEVRIES & CO. LTD |
| רישיון | תאריך הגשה: 12/2011. רישיון מתאריך: 02/2014 |
| תאריך עדכון אחרון | 14/01/19 |
דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.
- דף התרופה: דוסטקסל אקטביס - Docetaxel actavis
- לדריסה ידנית של פרטי התרופה: ניתן לערוך את דף התרופה לעיל. לדוגמה החליפו את:
{{תרופה/דוסטקסל אקטביס - Docetaxel actavis}}
ב:
{{תרופה/דוסטקסל אקטביס - Docetaxel actavis
| שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר)
}}
